{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Raynaud",
    "query": {
      "condition": "Raynaud"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Raynaud&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T01:05:50.988Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01233999",
      "title": "Botulinum Toxin in the Treatment of Raynaud's",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Raynaud's Syndrome"
      ],
      "interventions": [
        {
          "name": "botulinum toxin A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 10,
      "start_date": "2010-10",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-05-22T01:05:50.988Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01233999"
    },
    {
      "nct_id": "NCT02228850",
      "title": "Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Raynaud's Phenomenon Secondary to Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Alprostadil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 35,
      "start_date": "2014-11",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-03-22",
      "last_synced_at": "2026-05-22T01:05:50.988Z",
      "location_count": 4,
      "location_summary": "Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02228850"
    },
    {
      "nct_id": "NCT00934427",
      "title": "Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Raynaud Disease"
      ],
      "interventions": [
        {
          "name": "0.9% nitroglycerin in TAM cream",
          "type": "DRUG"
        },
        {
          "name": "vehicle cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediQuest Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 100,
      "start_date": "2009-06",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2010-07-20",
      "last_synced_at": "2026-05-22T01:05:50.988Z",
      "location_count": 11,
      "location_summary": "Redwood City, California • Farmington, Connecticut • Boston, Massachusetts + 8 more",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00934427"
    },
    {
      "nct_id": "NCT04898036",
      "title": "Phototherapy For Treatment Of Raynaud's Phenomenon",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Raynaud Disease",
        "Raynaud Phenomenon",
        "Raynaud Syndrome"
      ],
      "interventions": [
        {
          "name": "Blue Light Therapy",
          "type": "DEVICE"
        },
        {
          "name": "Sham Light Therapy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-08",
      "completion_date": "2023-03",
      "has_results": false,
      "last_update_posted_date": "2023-01-06",
      "last_synced_at": "2026-05-22T01:05:50.988Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04898036"
    },
    {
      "nct_id": "NCT00378521",
      "title": "Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Raynaud's Disease",
        "Raynaud's Disease Secondary to Scleroderma",
        "Raynaud's Disease Secondary to Autoimmune Disease"
      ],
      "interventions": [
        {
          "name": "MQX-503",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediQuest Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 15,
      "start_date": "2006-07",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2007-05-30",
      "last_synced_at": "2026-05-22T01:05:50.988Z",
      "location_count": 1,
      "location_summary": "Renton, Washington",
      "locations": [
        {
          "city": "Renton",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00378521"
    },
    {
      "nct_id": "NCT02370784",
      "title": "Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Scleroderma"
      ],
      "interventions": [
        {
          "name": "atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Robyn T. Domsic, MD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2015-02",
      "completion_date": "2019-12-15",
      "has_results": true,
      "last_update_posted_date": "2020-08-12",
      "last_synced_at": "2026-05-22T01:05:50.988Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02370784"
    },
    {
      "nct_id": "NCT03639766",
      "title": "The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Raynaud Phenomenon"
      ],
      "interventions": [
        {
          "name": "AbobotulinumtoxinA",
          "type": "DRUG"
        },
        {
          "name": "Saline solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Central Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2018-08-31",
      "completion_date": "2020-01-31",
      "has_results": true,
      "last_update_posted_date": "2021-06-30",
      "last_synced_at": "2026-05-22T01:05:50.988Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03639766"
    },
    {
      "nct_id": "NCT00266669",
      "title": "Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Raynaud's Disease"
      ],
      "interventions": [
        {
          "name": "Topical organogel with nitroglycerin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediQuest Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 200,
      "start_date": "2005-12",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2007-08-08",
      "last_synced_at": "2026-05-22T01:05:50.988Z",
      "location_count": 17,
      "location_summary": "Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00266669"
    },
    {
      "nct_id": "NCT00048763",
      "title": "Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Raynaud's Disease"
      ],
      "interventions": [
        {
          "name": "Pletal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka America Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "5 Years to 16 Years"
      },
      "enrollment_count": 75,
      "start_date": "2001-10",
      "completion_date": "2003-06",
      "has_results": false,
      "last_update_posted_date": "2005-07-19",
      "last_synced_at": "2026-05-22T01:05:50.988Z",
      "location_count": 18,
      "location_summary": "Anchorage, Alaska • Fresno, California • Madera, California + 15 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00048763"
    },
    {
      "nct_id": "NCT02374320",
      "title": "Exparel as a Nerve Block for Severe Hand Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "CREST Syndrome",
        "Peripheral Vascular Disease",
        "Raynaud Disease",
        "Scleroderma, Diffuse"
      ],
      "interventions": [
        {
          "name": "liposomal bupivacaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jose Soberon, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2014-11",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-05-22T01:05:50.988Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02374320"
    }
  ]
}